FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Precigen's Trailing 12-Month Free Cash Flow is €-100.57 Mil, and Market Cap is €1,724.95 Mil. Therefore, Precigen's FCF Yield % for today is -5.96%.
The historical rank and industry rank for Precigen's FCF Yield % or its related term are showing as below:
STU:I5X'
s FCF Yield % Range Over the Past 10 Years
Min: -45.25 Med: -10.8 Max: 1.18
Current: -5.96
During the past 13 years, the highest FCF Yield % of Precigen was 1.18%. The lowest was -45.25%. And the median was -10.80%.
STU:I5X's FCF Yield % is ranked better than 59.73% of 1408
companies
in the Biotechnology industry
Industry Median: -9.305
vs STU:I5X: -5.96
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Precigen FCF Yield % Related Terms
Precigen FCF Yield % Historical Data
* Premium members only.
The historical data trend for Precigen's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:I5X vs KARD, SLBT, GENB: FCF Yield % Comparison
For the Biotechnology subindustry, Precigen's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Precigen's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (STU:I5X) has a FCF Yield % of -5.96 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Precigen and its competitors. According to the industry distribution chart, Precigen ranks #567 out of 1408 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Precigen's FCF Yield % too high?
Precigen's current FCF Yield % is -5.96. Based on the distribution chart, Precigen ranks #567 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Precigen has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Precigen's FCF Yield % compare to KARD and SLBT?
According to the Biotechnology industry distribution chart, Precigen ranks #567 out of 1408 companies for FCF Yield %. This puts Precigen in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Precigen and its competitors. Precigen's current FCF Yield % is -5.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Fairly Valued. The stock's GF Value™ is €5.16, compared to a current price of €4.80 — trading 7% below its estimated fair value. The current FCF Yield % is -5.96. Precigen's overall GF Score™ is 59/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Precigen (STU:I5X), the current FCF Yield % is -5.96 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (STU:I5X) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be undervalued.
The current stock price of €4.80 is trading 7% below its estimated GF Value™ of €5.16.
GuruFocus considers Precigen to be Fairly Valued.
Key valuation signals for STU:I5X:
FCF Yield %: -5.96
GF Value™: €5.16 vs. price of €4.80 (7% below fair value)
No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
59GF Score
Get the complete analysis for STU:I5X
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I5X has been successfully added to your 
